Impact assessment of administering
Oral Cholera Vaccine in selected cholera vulnerable districts of
- An Vaccine implementation Research by ICMR- NICED in
collaboration with State Public Health System, Govt of West
Cholera remains a global public health problem with
developing countries bearing the burnt many folds. WHO - Global
Task Force on Cholera Control (GTFCC) has declared to End
Cholera by 2030 to which India is also committed as a Nation.
Prevention of Cholera outbreak always remained a challenge in
countries like India where there are lots of slum populations
with high population density. Achieving cholera control through
improving water, hygiene, and sanitation may not be feasible at
times and require sustained effort and commitment. In such a
situation, the Oral Cholera Vaccine (OCV) is an important
intervention to address immediately the cholera outbreak menace.
In this regard, ICMR-NICED Kolkata is taking the initiative
through an ICMR-funded project for health system implementation
of OCV in selected cholera-vulnerable districts of West Bengal
utilizing the state health machinery so that effectiveness,
challenges, and future policy decisions on requirements of
programmatic introduction of OCV may be monitored from real
health system perspective.
Euvichol-Plus is an OCV containing inactivated whole cell
(WC) of Vibrio cholerae O1 and O139 as active
ingredients. It is very safe and around 65% efficacious as
evidenced from earlier Randomized Control Trials. The study
vaccine (Euvichol-Plus) has been registered in multiple
countries, with WHO prequalification for use in subjects 1 year
and above. Euvichol-Plus has been procured from UN agencies at
subsidized rate, comprising more than 90% of OCV supply to
cholera-endemic countries worldwide.
The primary objective is to evaluate the impact of OCV
implementation in cholera-endemic zones of West Bengal in a real
time situation through a mass vaccination campaign using the
public healthcare delivery system. Other specific research
components will also be included, like :
- Age group of target population: children of 1 year and
above from cholera-endemic areas, excluding
pregnant/lactating women and seriously ill individuals.
- Oral cholera vaccine (OCV), Euvichol-Plus, will be
administered through urban municipality primary health
centres or other booths at selected Urban wards (areas with
dense clusters in city study map above) with a dosing
schedule of Day 0 and Day 14, targeting a total population
of around 50,000.
- The vaccine, WHO-prequalified in 2017, has demonstrated
sufficient safety and immunogenicity.
- Post-vaccination, diarrhoeal disease surveillance
network will be in place to monitor and document diarrheal